The effects of Ontario’s compulsory school immunization show there are advantages and disadvantages of requiring vaccination.
L’expertise universitaire, l’exigence journalistique
Articles sur Pfizer
Affichage de 41 à 60 de 114 articles
The COVID pandemic is giving drug companies an opportunity to reset their image. So how did they get so big and their credibility sink so low?
The international evidence so far shows COVID vaccines are safe for pregnant women and effective at preventing severe disease.
If Australians won’t take the AstraZeneca vaccine, we must donate it to save lives elsewhere, especially while we queue-jump for more Pfizer doses.
ATAGI is grappling with competing concerns, considerable uncertainty, and a constantly changing landscape.
The prime minister has condemned the anti-lockdown rallies while defending free speech.
As Los Angeles County again mandates masking indoors – even for the fully vaccinated – local health officials in the U.S. are closely eyeing their own COVID-19 vaccination and infection rates.
As many teens and adults in the US restart their social lives, parents of children under the age of 12 wonder when their kids will also be able to experience the freedom that comes with vaccination.
If Big Pharma wants to achieve the ultimate image makeover, it must capitalize on the current public good will about its COVID-19 vaccines by prioritizing socially responsible practices.
Major companies and business groups are being brought into the rollout effort to speed up the rate of vaccination, opening the way potentially for workplace jabs later in the year.
South Africa has clearly suffered the consequences of poor strategic decisions to this point. It doesn’t need to continue along these lines.
Just like your memory, which improves by repeated viewing or listening with a break in between, our immune memory improves with repeated exposure.
This myth is still circulating online. Here’s why the chance of this happening is next to zero.
While it’s potentially promising, there’s not enough information yet to determine if the vaccine is safe and effective.
The vaccine works by the same principles as the Pfizer and Moderna vaccines, and could be manufactured in Australia.
Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
Corporations need to weigh up significant risks against wider benefits.
Australia is now rolling out the Pfizer vaccine to people aged under 50, with the 40-49 age group newly eligible. Here’s what you can expect.
This treatment would work by targeting the SARS-CoV-2 virus itself and stopping it in its tracks. The evidence we have so far is promising, but it’s still very early days.
The COVID-19 variant responsible for Victoria’s latest outbreak is one of three Indian variant sub-types, which spreads more easily than the original strain. Here’s what we know so far.
Les contributeurs les plus fréquents
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Medicine, University of Virginia
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professorial Fellow, University of Canberra
-
Instructor of Human Immunology, Emory University
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Associate Professor of Biology, Rochester Institute of Technology
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Joel Lexchin est un·e adhérent·e de The Conversation
Professor Emeritus of Health Policy and Management, York University, Canada
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW Sydney
